Soligenix Seeks Funding for Bundibugyo Ebola Vaccine Development
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
Benzinga
Image: Benzinga
Soligenix, Inc. is applying for funding from the Coalition for Epidemic Preparedness Innovations to develop a thermostable vaccine for Bundibugyo virus, leveraging prior research on filovirus vaccines. The application is due June 12, 2026, aiming to enhance global vaccination efforts.
- 01Soligenix's vaccine development is in collaboration with Dr. Axel Lehrer from the University of Hawaiʻi at Mānoa.
- 02The proposed vaccine utilizes a thermostabilization platform that allows storage at ambient temperatures.
- 03Previous studies showed up to 100% protection in non-human primates using their filovirus vaccines.
- 04The Bundibugyo virus outbreak has resulted in 65 deaths and 397 confirmed cases in the Democratic Republic of Congo and Uganda as of June 4, 2026.
- 05CEPI has committed $3.6 billion to epidemic preparedness since its inception.
Advertisement
In-Article Ad
Soligenix, Inc., based in Princeton, New Jersey, is preparing to submit a proposal to the Coalition for Epidemic Preparedness Innovations (CEPI) for funding to develop a vaccine against the Bundibugyo virus (BDBV). The deadline for applications is June 12, 2026. This initiative builds on prior work with bivalent and trivalent vaccines targeting Ebola and related viruses, demonstrating strong immunogenicity and efficacy in non-human primates. Dr. Axel Lehrer from the University of Hawaiʻi at Mānoa is collaborating with Soligenix on this project, emphasizing the potential of a single-vial subunit vaccine that can be stored at ambient temperatures, simplifying logistics in virus-endemic regions. The Bundibugyo virus outbreak has been declared a Public Health Emergency of International Concern by the World Health Organization, with 65 confirmed deaths reported as of June 4, 2026. Soligenix aims to leverage its established ThermoVax® platform to enhance vaccine stability and accessibility, which could significantly improve vaccination efforts globally.
Advertisement
In-Article Ad
The development of a Bundibugyo virus vaccine could significantly enhance public health responses in regions affected by the virus.
Advertisement
In-Article Ad
Reader Poll
How important do you think vaccine development is for addressing viral outbreaks?
Connecting to poll...
More about Coalition for Epidemic Preparedness Innovations
Scientists Develop New Ebola Vaccine Amid Ongoing Outbreak in DRC
The Conversation • Jun 4, 2026
Ebola in Africa Centrale: Le Cause della Diffusione e Nuovi Sviluppi Vaccinali
La Repubblica • Jun 4, 2026
Global Coalition Allocates $62 Million for Ebola Vaccine Development Amid Outbreak
Stat • Jun 2, 2026
Read the original article
Visit the source for the complete story.